Testing a new liquid form of nintedanib for IPF
Part of Lungs & breathing clinical trials.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have been diagnosed with IPF within the last 5 years
- Your lung function tests show a certain level of breathing ability (FVC at least 45% of normal, and DLCO between 30-80% of normal)
- You have not taken nintedanib or pirfenidone in the last 3 months
- You do not have serious heart, bleeding, liver, or kidney problems
- You are willing to use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This study tests whether adding a cough suppressant called dextromethorphan to the standard IPF medication nintedanib helps improve cough and lung function better than nintedanib alone. It is a 12-week treatment phase with a 1-week follow-up, designed for people with moderate IPF.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.